Leap Therapeutics Secures $58.88 Million for Digital Asset Strategy

Biotech firm Leap Therapeutics has secured a significant funding round of $58.88 million, led by Winklevoss Capital. This investment will be used to launch a dedicated digital asset financial strategy. 🧠 Winklevoss Capital’s expertise in this space will support Leap’s development and implementation of its digital asset strategy. They plan to actively invest in digital assets with the goal of maximizing long-term returns for shareholders. 📈 A portion of these funds will be directed towards advancing Leap Therapeutics’ existing therapeutic programs, including FL-501 and sirexatamab.